89Zr-DFO-nimotuzumab

**89Zr-DFO-nimotuzumab** is an investigational EGFR-targeted immunoPET imaging agent. It consists of the humanized anti-EGFR monoclonal antibody nimotuzumab conjugated to the desferrioxamine chelator and radiolabeled with the positron-emitting isotope zirconium-89. Following intravenous administration, it is intended to bind EGFR-expressing tumor cells and enable noninvasive PET/CT visualization and measurement of tumor EGFR expression, potentially supporting selection of patients for EGFR-directed therapy. The University of Saskatchewan-sponsored clinical study NCT04235114 is evaluating the tracer in lung and colorectal cancers. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04235114))

Other names

[89Zr]Zr-DFO-nimotuzumab89Zr-nimotuzumab